Dana J. Lukin, Ph.D.
Affiliations: | 2006 | Icahn School of Medicine at Mount Sinai, New York, NY, United States |
Area:
Molecular Biology, Oncology, Cell BiologyGoogle:
"Dana Lukin"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| James J. Manfredi | grad student | 2006 | Mount Sinai School of Medicine | |
| (Cell cycle regulation by the tumor suppressor p53.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kumar A, Teslova T, Taub E, et al. (2020) Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications. Digestive Diseases and Sciences |
| Lukin DJ, Kumar A, Hajifathalian K, et al. (2020) Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease. Gastroenterology |
| Kumar A, Lukin D, Battat R, et al. (2020) Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis. Journal of Gastroenterology |
| Axelrad J, Colombel JF, Scherl E, et al. (2020) P729 The SAPPHIRE registry: Safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a HIstoRy of CancEr Journal of Crohns & Colitis. 14 |
| Agrawal M, Cohen-Mekelburg S, Kayal M, et al. (2019) Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors. Alimentary Pharmacology & Therapeutics |
| Lukin DJ, Lawlor G, Hudesman DP, et al. (2018) Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile. Inflammatory Bowel Diseases |
| Agrawal M, Cohen-Mekelburg S, Kayal M, et al. (2018) P826 Lower socioeconomic status is associated with disability in inflammatory bowel disease patients Journal of Crohn's and Colitis. 12: S533-S534 |
| Brave M, Lukin DJ, Mani S. (2015) Microbial control of intestinal innate immunity. Oncotarget. 6: 19962-3 |
| Lukin DJ, Carvajal LA, Liu WJ, et al. (2015) p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints. Molecular Cancer Research : McR. 13: 16-28 |
| Westphalen CB, Asfaha S, Hayakawa Y, et al. (2014) Long-lived intestinal tuft cells serve as colon cancer-initiating cells. The Journal of Clinical Investigation. 124: 1283-95 |